Therapeutic targeting of adipose tissue macrophages ameliorates liver fibrosis in non-alcoholic fatty liver disease.
Adipose tissue inflammation
Dextran dexamethasone conjugates
Drug delivery
Liver injury
Nanomedicine
Nanoparticle
Non-alcoholic steatohepatitis
Targeted therapy
Journal
JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
11
10
2022
revised:
02
05
2023
accepted:
05
06
2023
medline:
13
9
2023
pubmed:
13
9
2023
entrez:
13
9
2023
Statut:
epublish
Résumé
: The accumulation of adipose tissue macrophages (ATMs) in obesity has been associated with hepatic injury. However, the contribution of ATMs to hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD) remains to be elucidated. Herein, we investigate the relationship between ATMs and liver fibrosis in patients with patients with NAFLD and evaluate the impact of modulation of ATMs over hepatic fibrosis in an experimental non-alcoholic steatohepatitis (NASH) model. Adipose tissue and liver biopsies from 42 patients with NAFLD with different fibrosis stages were collected. ATMs were characterised by immunohistochemistry and flow cytometry and the correlation between ATMs and liver fibrosis stages was assessed. Selective modulation of the ATM phenotype was achieved by Patients with NAFLD presented an increased accumulation of pro-inflammatory ATMs that correlated with hepatic fibrosis. Long-term modulation of ATMs significantly reduced pro-inflammatory phenotype and ameliorated adipose tissue inflammation. Moreover, ATMs modulation was associated with an improvement in steatosis and hepatic inflammation and significantly reduced fibrosis progression in an experimental NASH model. Pro-inflammatory ATMs increase in parallel with fibrosis degree in patients with NAFLD and their modulation in an experimental NASH model improves liver fibrosis, uncovering the potential of ATMs as a therapeutic target to mitigate liver fibrosis in NAFLD. We report that human adipose tissue pro-inflammatory macrophages correlate with hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD). Furthermore, the modulation of adipose tissue macrophages (ATMs) by dextran-nanocarrier conjugated with dexamethasone shifts the pro-inflammatory phenotype of ATMs to an anti-inflammatory phenotype in an experimental murine model of non-alcoholic steatohepatitis. This shift ameliorates adipose tissue inflammation, hepatic inflammation, and fibrosis. Our results highlight the relevance of adipose tissue in NAFLD pathophysiology and unveil ATMs as a potential target for NAFLD.
Sections du résumé
Background & Aims
UNASSIGNED
: The accumulation of adipose tissue macrophages (ATMs) in obesity has been associated with hepatic injury. However, the contribution of ATMs to hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD) remains to be elucidated. Herein, we investigate the relationship between ATMs and liver fibrosis in patients with patients with NAFLD and evaluate the impact of modulation of ATMs over hepatic fibrosis in an experimental non-alcoholic steatohepatitis (NASH) model.
Methods
UNASSIGNED
Adipose tissue and liver biopsies from 42 patients with NAFLD with different fibrosis stages were collected. ATMs were characterised by immunohistochemistry and flow cytometry and the correlation between ATMs and liver fibrosis stages was assessed. Selective modulation of the ATM phenotype was achieved by
Results
UNASSIGNED
Patients with NAFLD presented an increased accumulation of pro-inflammatory ATMs that correlated with hepatic fibrosis. Long-term modulation of ATMs significantly reduced pro-inflammatory phenotype and ameliorated adipose tissue inflammation. Moreover, ATMs modulation was associated with an improvement in steatosis and hepatic inflammation and significantly reduced fibrosis progression in an experimental NASH model.
Conclusions
UNASSIGNED
Pro-inflammatory ATMs increase in parallel with fibrosis degree in patients with NAFLD and their modulation in an experimental NASH model improves liver fibrosis, uncovering the potential of ATMs as a therapeutic target to mitigate liver fibrosis in NAFLD.
Impact and implications
UNASSIGNED
We report that human adipose tissue pro-inflammatory macrophages correlate with hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD). Furthermore, the modulation of adipose tissue macrophages (ATMs) by dextran-nanocarrier conjugated with dexamethasone shifts the pro-inflammatory phenotype of ATMs to an anti-inflammatory phenotype in an experimental murine model of non-alcoholic steatohepatitis. This shift ameliorates adipose tissue inflammation, hepatic inflammation, and fibrosis. Our results highlight the relevance of adipose tissue in NAFLD pathophysiology and unveil ATMs as a potential target for NAFLD.
Identifiants
pubmed: 37701336
doi: 10.1016/j.jhepr.2023.100830
pii: S2589-5559(23)00161-1
pmc: PMC10494470
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100830Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
All authors declare no conflicts of interest related to this manuscript. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
Diabetes. 2010 Jul;59(7):1648-56
pubmed: 20357360
Proc Natl Acad Sci U S A. 2018 May 29;115(22):E5096-E5105
pubmed: 29760084
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
J Immunol. 2016 Nov 1;197(9):3735-3745
pubmed: 27698011
Diabetes. 2006 Jun;55(6):1554-61
pubmed: 16731817
J Hepatol. 2012 May;56(5):1152-1158
pubmed: 22245892
Nat Commun. 2021 Jan 4;12(1):102
pubmed: 33397994
Gastroenterology. 2015 Sep;149(3):635-48.e14
pubmed: 26028579
Gut. 2018 Jul;67(7):1317-1327
pubmed: 29074725
J Hepatol. 2019 Nov;71(5):1012-1021
pubmed: 31301321
Front Med (Lausanne). 2021 Apr 14;8:615978
pubmed: 33937277
Front Endocrinol (Lausanne). 2021 Oct 28;12:760860
pubmed: 34777255
ACS Nano. 2022 Feb 22;16(2):1999-2012
pubmed: 35107994
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Hepatology. 2017 May;65(5):1557-1565
pubmed: 28130788
J Immunol. 2011 Nov 15;187(10):5408-18
pubmed: 22013115
Semin Liver Dis. 2015 May;35(2):132-45
pubmed: 25974899
Sci Rep. 2017 Feb 15;7:42665
pubmed: 28198418
JHEP Rep. 2019 Feb 23;1(1):30-43
pubmed: 32149275
Ann Transl Med. 2021 Apr;9(8):729
pubmed: 33987427
Nat Protoc. 2021 May;16(5):2542-2563
pubmed: 33864055
Hepatology. 2022 Apr;75(4):1038-1049
pubmed: 35023202
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Hepatology. 2021 Sep;74(3):1287-1299
pubmed: 33743554
Int J Mol Sci. 2017 Jul 29;18(8):
pubmed: 28758929
J Pharm Pharm Sci. 2014;17(3):371-92
pubmed: 25224349
Metabolism. 2016 Aug;65(8):1062-79
pubmed: 26725002
Diabetologia. 2018 Apr;61(4):942-953
pubmed: 29333574
J Hepatol. 2013 Jun;58(6):1218-29
pubmed: 23238106
Front Cardiovasc Med. 2020 Feb 25;7:22
pubmed: 32158768
Sci Rep. 2021 Sep 29;11(1):19396
pubmed: 34588551
Cell. 2019 Jul 25;178(3):686-698.e14
pubmed: 31257031
Cell. 2017 Oct 5;171(2):372-384.e12
pubmed: 28942920
Methods Mol Biol. 2019;1966:225-236
pubmed: 31041751
ACS Nano. 2016 Jul 26;10(7):6952-62
pubmed: 27281538
Metabolism. 2022 Jan;126:154925
pubmed: 34740573
Diabetes. 2007 Apr;56(4):1010-3
pubmed: 17287468